Skip to content
value.today

Enobia Pharma Corp

Total raised
$85 M
3 rounds on record
Latest round
$20 M
Aug 2011
First round on record
Aug 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Enobia Pharma Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2011$20 MNo. 3$10 to $50 million

Enobia Pharma Corp: Raise no. 3, Aug 2011

Investors in this round

3 investors had bought by the notice of Aug 24, 2011: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $40 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$1,300,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric L. Trachtenberg · Executive Officer
  • Jeffrey Mack · Executive Officer
  • Robert Heft · Executive Officer, Director
  • David L. Bonita · Director
  • Frederic L. Price · Director
  • Jonathan L. Silverstein · Director
  • Luc L. Mainville · Director
  • Richard L. Meadows · Director
  • Thomas L. Schuetz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “$650,000 is payable in connection with the first tranche of securities issued. In addition, Enobia Pharma Corp. has agreed to reimburse the placement agent for its out-of-pocket expenses up to a specified amount.”
  • On the amounts: “Subject to the terms and conditions of the stock purchase agreement, investors have committed to purchase $39,999,999.55 of securities in two equal tranches.”
  • On the use of proceeds: “The net proceeds of the offering will be used for general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors.”

Signed by Eric L. Trachtenberg, Corporate Secretary. Source: SEC Form D, newest notice filed Aug 24, 2011. Read the notice at the SEC.

equitySEC
Mar 2011$15 MNo. 2$10 to $50 million

Enobia Pharma Corp: Raise no. 2, Mar 2011

Investors in this round

7 investors had bought by the notice of Apr 1, 2011: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $47 M offered; $32 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Mack · Executive Officer
  • Luc Cournoyer · Executive Officer
  • Robert Heft · Director, Executive Officer
  • David Bonita · Director
  • Frederic Price · Director
  • Jonathan Silverstein · Director
  • Luc Mainville · Director
  • Richard Meadows · Director
  • Thomas Schuetz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Subject to fulfillment of conditions, investors have committed to purchase $45,000,000 of securities in three equal tranches. Additional investors have been offered up to an aggregate of $1,969,070 of securities in tranches, but have not yet committed.”
  • On the use of proceeds: “Proceeds are applied to general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors.”

Signed by Robert Heft, President and CEO. Source: SEC Form D, newest notice filed Apr 1, 2011. Read the notice at the SEC.

equitySEC
Aug 2009$50 MNo. 1$50 to $250 million

Enobia Pharma Corp: Raise no. 1, Aug 2009

Investors in this round

8 investors had bought by the notice of Dec 13, 2010: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Mack · Executive Officer
  • Luc Cournoyer · Executive Officer
  • Robert Heft · Director, Executive Officer
  • David Bonita · Director
  • Frederic Price · Director
  • Jonathan Silverstein · Director
  • Luc Mainville · Director
  • Richard Meadows · Director
  • Thomas Schuetz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds are applied to general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors.”

Signed by Robert Heft, President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Dec 13, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Enobia Pharma Corp had revenue of up to $1 million when it filed its newest notice of a funding round (Aug 2011).

    SEC Form D (revenue range) · Aug 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2011

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Enobia Pharma Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Enobia Pharma Corp
NameRoleNamed in
Eric L. TrachtenbergExecutive officerAug 2011
Jeffrey MackExecutive officerAug 2011
Robert HeftExecutive officerAug 2011
Luc CournoyerExecutive officerApr 2011
David L. BonitaDirectorAug 2011
Frederic L. PriceDirectorAug 2011
Jonathan L. SilversteinDirectorAug 2011
Luc L. MainvilleDirectorAug 2011
Richard L. MeadowsDirectorAug 2011
Robert HeftDirectorAug 2011
Thomas L. SchuetzDirectorAug 2011
David BonitaDirectorApr 2011
Frederic PriceDirectorApr 2011
Jonathan SilversteinDirectorApr 2011
Luc MainvilleDirectorApr 2011
Richard MeadowsDirectorApr 2011
Thomas SchuetzDirectorApr 2011